A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines

Inclusion Criteria:

- Patients exhibiting moderate [2] to severe [3] superficial, vertical perioral lines
on the 5-point Merz® validated scale for assessment of superficial perioral lines

- Females and males in good general health over the age of 18 years old

Must be willing to give and sign a HIPAA form, informed consent form and a photographic
release form

- Patient is planning to undergo Restylane® Silk and Belotero Balance® injections

- For female patient of childbearing potential, must have had a regular menstrual cycle
prior to study entry (a female is considered of childbearing potential unless she is
postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal
ligation) and is willing to use an acceptable form of birth control during the entire
course of the study [i.e., acceptable methods of birth control are oral
contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®,
double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of
partner with a documented second acceptable method of birth control should the
patient become sexually active]. All systemic birth control measures must be in
consistent use at least 30 days prior to study participation

- Negative urine pregnancy test results at the time of study entry (if applicable)

- Must be willing to comply with study regimen and complete the entire course of the
study.

Exclusion Criteria:

- A patient with any uncontrolled systemic disease. A potential patient in whom therapy
for a systemic disease is not yet stabilized will not be considered for entry into
the study

A patient with a significant history or current evidence of a medical, psychological or
other disorder that, in the investigator's opinion, would preclude enrollment into the
study.

- A patient with a known hypersensitivity to any of the components of the study
medications

- A patient who is actively smoking or plans to smoke at any time of the duration of
this study

- A patient with an active skin condition/disease that might interfere with the
diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema,
psoriasis, seborrheic dermatitis, herpes labialis)

- A patient planning any other cosmetic procedure to their facial area during the study
period, other than the treatments that will be performed by the investigator

- A patient using any topical (prescription or over the counter) medicated creams,
lotions, gels, balms, powders, etc. on the treatment areas during the study period

- A patient receiving any topical products containing alpha-hydroxy acids, salicylic
acid, and vitamins C or D (includes derivatives thereof) on the perioral areas within
7 days prior to or during the study period, other than the study products

- A patient receiving any investigational drug and/or has had a microdermabrasion
(light or medium skin peel) treatment on their perioral areas within 30 days prior to
or during the study period

- A patient using any topical tretinoin product or derivative on their perioral areas
within 12 weeks prior to or during the study period

- A patient receiving a chemical peel, any systemic steroids, a non-ablative laser,
light or radio frequency treatment and/or has had a dermabrasion (deep skin peel) or
ablative laser treatments on their perioral areas must have discontinued the
drug/treatment and/or had the procedure at least 6 months prior to entering the study

- A patient that has previously been treated with botulinum toxin in the perioral areas
within the past six months

- A patient that has previously been treated with dermal filler in the perioral areas
within the past year

- A patient that with a history of allergic reaction to a dermal filler or lidocaine

- A patient that with a history of a permanent filler to the perioral areas

- A female patient who is pregnant, nursing an infant or planning a pregnancy during
the study [throughout the course of the study, women of child-bearing potential must
use reliable forms of contraception (i.e., oral contraceptive, intrauterine device,
abstinence, or spermicides and condoms used in combination)]

- Current participation or participation within 30 days prior to the start of this
study in a drug or other investigational research study.